KR20040009184A - 주사용 이버멕틴 조성물 및 그 제조방법 - Google Patents
주사용 이버멕틴 조성물 및 그 제조방법 Download PDFInfo
- Publication number
- KR20040009184A KR20040009184A KR1020020043030A KR20020043030A KR20040009184A KR 20040009184 A KR20040009184 A KR 20040009184A KR 1020020043030 A KR1020020043030 A KR 1020020043030A KR 20020043030 A KR20020043030 A KR 20020043030A KR 20040009184 A KR20040009184 A KR 20040009184A
- Authority
- KR
- South Korea
- Prior art keywords
- ivermectin
- composition
- injection
- group
- oil
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
군 | 처리 | 동물의 수(마리) | 자극성 점수 | ||
투여 후 7일째 | 투여 후 14일 째 | 투여 후 7일째 | 투여 후 14일째 | ||
평균 점수 | 평균 점수 | ||||
1 | 실시예 1 | 4 | 4 | 0 | 0 |
2 | 실시예 2 | 4 | 4 | 0 | 0 |
3 | 실시예 3 | 4 | 4 | 0.25 | 0 |
4 | 실시예 4 | 4 | 4 | 0 | 0 |
군 | 처리 | 개체 | 병리조직학적 성상 | ||||||||
부종 | 출혈 | 대식세포 | 염증 | 근섬유변성 | 광물질화 | 괴사 | 재생 | 다핵거세포 | |||
1 | 실시예 1 | 1 | + | + | + | + | - | + | + | + | - |
2 | + | + | + | + | + | + | + | + | - | ||
3 | + | - | - | - | - | - | - | - | - | ||
4 | - | - | - | - | - | - | - | - | - | ||
2 | 실시예 2 | 1 | + | + | + | - | - | - | - | + | - |
2 | - | - | - | - | - | - | - | - | - | ||
3 | + | + | + | ++ | + | - | - | - | - | ||
4 | + | - | - | - | - | - | - | - | - | ||
3 | 실시예 3 | 1 | - | + | + | ++ | + | + | + | + | - |
2 | + | - | - | - | - | - | - | - | - | ||
3 | - | - | - | - | - | - | - | - | - | ||
4 | + | + | + | - | - | + | - | - | - | ||
4 | 실시예 4 | 1 | - | - | - | + | + | - | - | - | - |
2 | - | - | - | - | - | - | - | - | - | ||
3 | - | + | - | - | - | - | - | - | - | ||
4 | + | + | + | ++ | + | + | + | + | - | ||
5 | 6% 초산 | 1 | ++ | ++ | ++ | +++ | + | +++ | ++ | + | ++ |
2 | ++ | +++ | ++ | +++ | + | ++ | +++ | + | ++ | ||
3 | ++ | +++ | ++ | ++++ | ++ | +++ | +++ | + | +++ | ||
4 | +++ | ++ | ++ | +++ | ++ | +++ | ++ | + | ++ | ||
6 | 생리 식염수 | 1 | - | - | - | - | - | - | - | + | - |
2 | - | - | - | + | - | - | - | - | - | ||
3 | - | + | - | + | - | - | - | + | - | ||
4 | - | - | - | + | - | - | - | - | - |
그룹 | 마리 | 투여량(ml) | 충란수(투여후) | ||||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |||
실시예 2 | 4 | 1.3 | 475 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
유벡틴 | 4 | 1.3 | 512.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
이보멕 | 4 | 1.3 | 450.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
인공감염군 | 4 | - | 512.5 | 462.5 | 575.0 | 450.0 | 600.0 | 487.5 | 437.5 | 562.5 | 462.5 |
대조군 | 5 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
그룹 | 마리 | 투여량(ml) | 충란수(투여후) | ||||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |||
실시예 2 | 4 | 1.3 | 675.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
유벡틴 | 4 | 1.3 | 512.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
이보멕 | 4 | 1.3 | 587.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
인공감염군 | 4 | - | 487.5 | 500.0 | 550.0 | 425.0 | 600.0 | 562.5 | 612.5 | 537.5 | 487.5 |
대조군 | 5 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
파리수(투여후) | ||||||
0 | 1 | 3 | ||||
마리 | 감소율(%) | 마리 | 감소율(%) | |||
실시예 2 | 평균 | 15.80 | 2.90 | 81.6 | 8.75 | 44.6 |
표준편차 | 3.27 | 1.37 | 1.92 | |||
유벡틴 | 평균 | 15.45 | 3.50 | 77.3 | 8.75 | 43.4 |
표준편차 | 3.28 | 1.50 | 1.92 | |||
이보멕 | 평균 | 15.80 | 3.50 | 77.8 | 9.05 | 42.7 |
표준편차 | 3.27 | 1.50 | 1.93 | |||
대조군 | 평균 | 14.80 | 14.70 | 0.7 | 11.90 | 19.6 |
표준편차 | 2.80 | 3.34 | 2.53 |
그룹 | 시험수 | 충란수(투여후) | ||||||||||
돼지 회충 | 돼지 편충 | |||||||||||
0 | 1 | 2 | 3 | 4 | 0 | 1 | 2 | 3 | 4 | |||
실시예 2 | 3 | 평균 | 367 | 0 | 0 | 0 | 0 | 333 | 0 | 0 | 0 | 0 |
표준편차 | 293 | 0 | 0 | 0 | 0 | 176 | 0 | 0 | 0 | 0 | ||
유벡틴 | 3 | 평균 | 367 | 17(1) | 0 | 0 | 0 | 267 | 17(1) | 0 | 0 | 0 |
표준편차 | 126 | 29 | 0 | 0 | 0 | 76 | 29 | 0 | 0 | 0 | ||
이보멕 | 3 | 평균 | 316 | 17(1) | 0 | 0 | 0 | 367 | 33(1) | 0 | 0 | 0 |
표준편차 | 225 | 29 | 0 | 0 | 0 | 161 | 58 | 0 | 0 | 0 | ||
대조군 | 3 | 평균 | 300 | 233 | 350 | 400 | 367 | 333 | 250 | 350 | 300 | 267 |
표준편차 | 132 | 144 | 150 | 265 | 236 | 202 | 150 | 132 | 100 | 176 |
Claims (5)
- 이버멕틴 0.5중량%w/v 내지 5중량%w/v, 공용매 0.5중량%w/v 내지 20중량%w/v, 계면활성제 2중량%w/v 내지 5중량%w/v 및 잔량으로서 오일을 포함하여 이루어지는 것을 특징으로 하는 주사용 이버멕틴 조성물.
- 제 1항에 있어서, 상기 공용매는 이소프로필미리스테이트, 글라이코퓨롤, 에틸알코올 또는 이들 중 2 이상의 혼합물로 이루어진 군으로부터 선택되는 것을 특징으로 하는 주사용 이버멕틴 조성물.
- 제 1항에 있어서, 상기 계면활성제는 솔비탄트리올레이트 또는 폴록사머로 이루어진 군으로부터 선택되는 것을 특징으로 하는 주사용 이버멕틴 조성물.
- 제 1항에 있어서, 상기 오일은 참기름인 것을 특징으로 하는 주사용 이버멕틴 조성물.
- 주사용 이버멕틴 조성물의 제조에 있어서,(1) 상온에서 이버멕틴을 이소프로필미리스테이트 또는 글라이코퓨롤의 용매로 용해하는 단계;(2) 무통화제제로서 벤질 알코올을 첨가하는 단계;(3) 계면활성제는 솔비탄 트리올레이트, 폴록사머 중에서 선택되는 어느 하나의 성분을 첨가하는 단계; 및(4) 오일을 첨가하여 용적을 100%로 조정하는 단계;로 이루어지는 것을 특징으로 하는 주사용 이버멕틴 조성물의 제조방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020043030A KR100600406B1 (ko) | 2002-07-22 | 2002-07-22 | 주사용 이버멕틴 조성물 및 그 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020043030A KR100600406B1 (ko) | 2002-07-22 | 2002-07-22 | 주사용 이버멕틴 조성물 및 그 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040009184A true KR20040009184A (ko) | 2004-01-31 |
KR100600406B1 KR100600406B1 (ko) | 2006-07-14 |
Family
ID=37318123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020043030A KR100600406B1 (ko) | 2002-07-22 | 2002-07-22 | 주사용 이버멕틴 조성물 및 그 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100600406B1 (ko) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0873127B1 (en) * | 1995-09-25 | 2006-11-15 | Ashmont Holdings Limited | Anthelmintic macrocyclic lactone compositions |
AU728221B2 (en) * | 1996-06-05 | 2001-01-04 | Ashmont Holdings Limited | Injectable compositions |
KR20000025762A (ko) * | 1998-10-14 | 2000-05-06 | 유충식 | 이버멕틴류의 가용화 조성물 |
KR20020067781A (ko) * | 2001-02-19 | 2002-08-24 | 주식회사 엘지씨아이 | 구충용 이버멕틴 주사제 조성물 및 그 제조방법 |
-
2002
- 2002-07-22 KR KR1020020043030A patent/KR100600406B1/ko active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR100600406B1 (ko) | 2006-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6653288B1 (en) | Injectable anthelmintic compositions and methods for using same | |
US6552002B2 (en) | Sustained-release compositions for parenteral administration | |
BR0307974B1 (pt) | composição parasiticida de ação prolongada contendo um composto de salicilanilida, uma espécie polimérica e pelo menos um outro composto antiparasita | |
JP2010535231A (ja) | 内部寄生虫駆除局所組成物 | |
JPH05246893A (ja) | 水素化ひまし油を含む長期持続性注射製剤 | |
SK281301B6 (sk) | Prostriedok na miestne podanie proti ektoparazitom a endoparazitom | |
TW200423871A (en) | Topical parasiticide formulations and methods of treatment | |
KR20080073700A (ko) | 벤즈이미다졸 비수성 조성물 | |
US9198430B2 (en) | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation | |
US6699847B2 (en) | Antiparasitic formulation | |
US6193989B1 (en) | Long acting injectable parasiticidal composition and the process for its preparation | |
EA009602B1 (ru) | Антипаразитарная композиция | |
KR100600406B1 (ko) | 주사용 이버멕틴 조성물 및 그 제조방법 | |
EP2211839A1 (en) | Long acting injectable formulations | |
JP5734959B2 (ja) | 外部寄生生物撲滅の方法および製剤 | |
JPH02290820A (ja) | 抗寄生虫剤 | |
HU206037B (en) | Process for producing nonaqueous pharmaceutical compositions for external use | |
KR20020067781A (ko) | 구충용 이버멕틴 주사제 조성물 및 그 제조방법 | |
KR920006913B1 (ko) | 구충제 제형 | |
HU208252B (en) | Process for producing solution against parasites and comprising avermectin derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120720 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130805 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140930 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150515 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160610 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170621 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190611 Year of fee payment: 14 |